In vivo characteristics of dopamine D-2 receptor occupancy by amisulpride in schizophrenia

被引:75
作者
Martinot, JL
PaillereMartinot, ML
Poirier, MF
DaoCastellana, MH
Loch, C
Maziere, B
机构
[1] INSERM, U344, F-91406 ORSAY, FRANCE
[2] HOP ST ANNE, SERV HOSP UNIV, F-75674 PARIS, FRANCE
[3] HOP BICETRE, PSYCHIAT SERV, LE KREMLIN BICETRE, FRANCE
[4] HOP LA PITIE SALPETRIERE, SERV PSCHIAT ADULTES, PARIS, FRANCE
关键词
schizophrenia; PET; neuroleptics; dopamine receptors;
D O I
10.1007/BF02245616
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The relationship between the daily oral dose of the benzamide amisulpride and the striatal D-2-dopamine receptors occupancy was investigated in 11 schizophrenic patients using positron emission tomography with Br-76-bromolisuride. The patients were studied before and during chronic treatment with amisulpride over a wide range of doses. The test-retest variability of the method was estimated to be 5.8% in a group of four patients receiving placebo. A curvilinear relationship was demonstrated between the amisulpride doses and the D-2-receptor occupancy. A range of 70-80% occupancy of the striatal D-2 receptors, suggested as an optimal interval for therapeutic action on positive psychotic symptoms, was obtained with doses of amisulpride ranging between 630 and 910 mg per day, while an occupancy of 85%, suggested to be associated with pronounced extrapyramidal side-effects, was reached with 1100 mg per day.
引用
收藏
页码:154 / 158
页数:5
相关论文
共 30 条
[1]  
ANDREASEN NC, 1987, PSYCHIAT PSYCHOBIOL, V2, P412
[2]   STRIATAL DOPAMINE RECEPTOR OCCUPANCY DURING AND FOLLOWING WITHDRAWAL FROM NEUROLEPTIC TREATMENT - CORRELATIVE EVALUATION BY POSITRON EMISSION TOMOGRAPHY AND PLASMA PROLACTIN LEVELS [J].
BARON, JC ;
MARTINOT, JL ;
CAMBON, H ;
BOULENGER, JP ;
POIRIER, MF ;
CAILLARD, V ;
BLIN, J ;
HURET, JD ;
LOCH, C ;
MAZIERE, B .
PSYCHOPHARMACOLOGY, 1989, 99 (04) :463-472
[3]   LOSS OF STRIATAL [BR-76] BROMOSPIPERONE BINDING-SITES DEMONSTRATED BY POSITRON TOMOGRAPHY IN PROGRESSIVE SUPRANUCLEAR PALSY [J].
BARON, JC ;
MAZIERE, B ;
LOCH, C ;
CAMBON, H ;
SGOUROPOULOS, P ;
BONNET, AM ;
AGID, Y .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1986, 6 (02) :131-136
[4]  
Boyer P, 1990, Mod Probl Pharmacopsychiatry, V24, P152
[5]   ANTI-SCHIZOPHRENIC DRUGS - CHRONIC TREATMENT ELEVATES DOPAMINE RECEPTOR-BINDING IN BRAIN [J].
BURT, DR ;
CREESE, I ;
SNYDER, SH .
SCIENCE, 1977, 196 (4287) :327-328
[6]   INVIVO ASSAY FOR NEUROLEPTIC RECEPTOR-BINDING IN THE STRIATUM - POSITRON TOMOGRAPHY IN HUMANS [J].
CAMBON, H ;
BARON, JC ;
BOULENGER, JP ;
LOCH, C ;
ZARIFIAN, E ;
MAZIERE, B .
BRITISH JOURNAL OF PSYCHIATRY, 1987, 151 :824-830
[7]   BEHAVIORAL DEFICITS INDUCED BY LOW-DOSES OF APOMORPHINE IN RATS - EVIDENCE FOR A MOTIVATIONAL AND COGNITIVE DYSFUNCTION WHICH DISCRIMINATES AMONG NEUROLEPTIC DRUGS [J].
CARNOY, P ;
RAVARD, S ;
WEMERMAN, B ;
SOUBRIE, P ;
SIMON, P .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1986, 25 (03) :503-509
[8]  
COSTA SJA, 1989, AMISULPRIDE, P93
[9]   DOPAMINE RECEPTOR-BINDING PREDICTS CLINICAL AND PHARMACOLOGICAL POTENCIES OF ANTI-SCHIZOPHRENIC DRUGS [J].
CREESE, I ;
BURT, DR ;
SNYDER, SH .
SCIENCE, 1976, 192 (4238) :481-483
[10]   AMISULPRIDE VERSUS HALOPERIDOL IN TREATMENT OF SCHIZOPHRENIC-PATIENTS - RESULTS OF A DOUBLE-BLIND-STUDY [J].
DELCKER, A ;
SCHOON, ML ;
OCZKOWSKI, B ;
GAERTNER, HJ .
PHARMACOPSYCHIATRY, 1990, 23 (03) :125-130